Medicare Will Continue to Cover 2 Expensive Cancer Drugs


July 1, 2011

The New York Times

Medicare confirmed on Thursday that it would continue to pay for two expensive cancer drugs that had been at the center of debate — Avastin from Genentech for breast cancer and Provenge from Dendreon for prostate cancer. 

A spokesman for the Centers for Medicare and Medicaid Services said the agency would continue to pay for Avastin for breast cancer, even if the Food and Drug Administration revoked the drug’s approval as a treatment for that disease... Read More